Report Sections

See All Reports

  • HP:0001658: Myocardial infarction
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001658: Myocardial infarction

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (24)


    Name (Synonyms) Correlation
    drug480 Biological data Wiki 0.38
    drug804 Clinical data Wiki 0.31
    drug24 1: Prone positioning Wiki 0.27
    Name (Synonyms) Correlation
    drug33 2: No instruction regarding positioning Wiki 0.27
    drug2461 Percutaneous Coronary Revascularization for STEMI Wiki 0.27
    drug179 Ad5FGF-4 Wiki 0.27
    drug3386 Tele-medicine platform Wiki 0.27
    drug2719 QFR Wiki 0.27
    drug1595 INM005 Wiki 0.27
    drug2792 RUC-4 Compound Wiki 0.27
    drug506 Blood Transfusion Wiki 0.27
    drug2918 Robot Assisted Percutaneous Cardiovascular Intervention Wiki 0.27
    drug17 14C-lazertinib Wiki 0.27
    drug20 18F-GP1 PET CT Wiki 0.27
    drug1583 IC14 Wiki 0.27
    drug427 BRII-198 Wiki 0.27
    drug40 300 mg of omega3-FA Wiki 0.27
    drug3951 mHealth Assessments Wiki 0.27
    drug243 Angiography Wiki 0.27
    drug1592 IMU-838 Wiki 0.19
    drug15 100 mg/mL Virazole Wiki 0.19
    drug52 50 mg/mL Virazole Wiki 0.19
    drug2351 Oseltamivir Wiki 0.10
    drug2505 Placebo Wiki 0.04

    Correlated MeSH Terms (40)


    Name (Synonyms) Correlation
    D009203 Myocardial Ischemia NIH 0.91
    D007238 Infarction NIH 0.68
    D003327 Coronary Disease NIH 0.51
    Name (Synonyms) Correlation
    D003324 Coronary Artery Disease NIH 0.40
    D002546 Ischemic Attack, Transient NIH 0.38
    D000787 Angina Pectoris NIH 0.38
    D054143 Heart Failure, Systolic NIH 0.38
    D013610 Tachycardia NIH 0.38
    D054058 Acute Coronary Syndrome NIH 0.36
    D000072657 ST Elevation Myocardial Infarction NIH 0.31
    D002561 Cerebrovascular Disorders NIH 0.27
    D019462 Syncope, Vasovagal NIH 0.27
    D013575 Syncope NIH 0.27
    D054144 Heart Failure, Diastolic NIH 0.27
    D016757 Death, Sudden, Cardiac NIH 0.27
    D013616 Tachycardia, Sinus NIH 0.27
    D017180 Tachycardia, Ventricular NIH 0.27
    D023921 Coronary Stenosis NIH 0.27
    D060050 Angina, Stable NIH 0.27
    D007022 Hypotension NIH 0.27
    D007511 Ischemia NIH 0.22
    D015673 Fatigue Syndrome, Chronic NIH 0.19
    D001281 Atrial Fibrillation NIH 0.19
    D009205 Myocarditis NIH 0.18
    D006333 Heart Failure NIH 0.17
    D006331 Heart Diseases NIH 0.16
    D016584 Panic Disorder NIH 0.15
    D011655 Pulmonary Embolism NIH 0.14
    D005356 Fibromyalgia NIH 0.13
    D003643 Death, NIH 0.13
    D014652 Vascular Diseases NIH 0.13
    D004617 Embolism NIH 0.13
    D013927 Thrombosis NIH 0.11
    D054556 Venous Thromboembolism NIH 0.10
    D020246 Venous Thrombosis NIH 0.08
    D013923 Thromboembolism NIH 0.07
    D020521 Stroke NIH 0.07
    D058186 Acute Kidney Injury NIH 0.06
    D013577 Syndrome NIH 0.05
    D002318 Cardiovascular Diseases NIH 0.05

    Correlated HPO Terms (20)


    Name (Synonyms) Correlation
    HP:0001677 Coronary artery atherosclerosis HPO 0.44
    HP:0001649 Tachycardia HPO 0.38
    HP:0002326 Transient ischemic attack HPO 0.38
    Name (Synonyms) Correlation
    HP:0001681 Angina pectoris HPO 0.38
    HP:0011703 Sinus tachycardia HPO 0.27
    HP:0005145 Coronary artery stenosis HPO 0.27
    HP:0002615 Hypotension HPO 0.27
    HP:0012668 Vasovagal syncope HPO 0.27
    HP:0001279 Syncope HPO 0.27
    HP:0004756 Ventricular tachycardia HPO 0.27
    HP:0001645 Sudden cardiac death HPO 0.27
    HP:0004757 Paroxysmal atrial fibrillation HPO 0.19
    HP:0012819 Myocarditis HPO 0.19
    HP:0001635 Congestive heart failure HPO 0.18
    HP:0002204 Pulmonary embolism HPO 0.15
    HP:0002625 Deep venous thrombosis HPO 0.08
    HP:0001297 Stroke HPO 0.07
    HP:0001907 Thromboembolism HPO 0.06
    HP:0001919 Acute kidney injury HPO 0.06
    HP:0001626 Abnormality of the cardiovascular system HPO 0.05

    Clinical Trials

    Navigate: Correlations   HPO

    There are 14 clinical trials


    1 Essential Arterial Hypotension and Allostasis Registry

    The essential arterial hypotension and allostasis registry is a prospective, observational research that has the purpose of demonstrating that essential blood pressure (BP) disorders and the associated comorbidities are a result of the inappropriate allostatic response to daily life stress. This required a functioning brain orchestrating the evaluation of the threat and choosing the response, this is a mind-mediated phenomenon. If the response is excessive it contributes to high BP, if deficient to low BP, and the BP itself will identify the allostatic pattern, which in turn will play an important role in the development of the comorbidities. To do so, consecutive patients of any age and gender that visit a cardiologist's office in Medellin, Colombia, are recruited. Individuals are classified according to their arterial BP and allostasis and follow them in time to see what kind of diseases develops the most (including BP) in the follow up according to the categorization of the characteristic chosen and after adjustment for confounder's variables. In addition, stress events with their date are registered. HYPOTHESIS The causes of the diseases are multifactorial. Physical, biochemical, psychological, social, and cultural dimensions of development dynamically interact to shape the health development process. A person´s health depends on their: 1. Biological and physiologic systems 2. External and internal environment (a) physical, b) internal behavioural and arousal state as registered by the brain. 3. Their interaction. The allostatic mechanisms to the internal and external stressors (allostatic load) involves a network composed by: 1. Functional systems; mediated by: 1. The Autonomic Nervous System 2. The endocrine system 3. The immune system 2. Structural changes: whenever the internal and/or external stressors are long lasting and/or strength enough, they may induce changes in: 1. Epigenetic, endophenotypes, polyphenism. 2. Plasticity 3. The interaction between a) and b). The network response do not affect exclusively the BP, propitiating the development of comorbidities, which may prompt strategies for prevention, recognition and ultimately, treatment. The allostatic model defines health as a state of responsiveness. The concept of psycho-biotype: The allostasis is the result of both: biological (allostasis) and psychological (psychostasis) abilities. It is proposed that both components behave in similar direction and magnitude. Immune disorders may be associated with the development of cancer. High BP population has a higher sympathetic and lower vagal tone, this has been associated with a decrease in the immune´s system function. Resources and energy depletion: Terms like weathering have been used to describe how exposures to different allostatic loads gradually scrape away at the protective coating that keeps people healthy. It is postulated that High BP individuals have more resources and energy.

    NCT02018497
    Conditions
    1. Blood Pressure
    2. Depression
    3. Panic Attack
    4. Fibromyalgia
    5. POTS
    6. Inappropriate Sinus Tachycardia
    7. Coronary Heart Disease
    8. Acute Coronary Syndrome (ACS)
    9. Acute Myocardial Infa
    10. Acute Myocardial Infarction (AMI)
    11. Cerebrovascular Disease (CVD)
    12. Transient Ischemic Attack (TIA)
    13. Atrial Fibrillation
    14. Diabetes Mellitus
    15. Cancer
    16. Systolic Heart Failure
    17. Diastolic Heart Failure
    18. Chronic Fatigue Syndrome
    19. Syncope
    20. Vasovagal Syncope
    MeSH:Fatigue Syndrome, Chronic Fibromyalgia Syncope Ischemic Attack, Transient Cerebrovascular Disorders Syncope, Vasovagal Heart Failure Atrial Fibrillation Heart Diseases Myocardial Infarction Acute Coronary Syndrome Hypotension Coronary Disease Tachycardia Heart Failure, Diastolic Heart Failure, Systolic Tachycardia, Sinus Syndrome Panic Disorder
    HPO:Atrial fibrillation Carotid sinus syncope Congestive heart failure Hypotension Left ventricular dysfunction Myocardial infarction Paroxysmal atrial fibrillation Right ventricular failure Sinus tachycardia Syncope Tachycardia Transient ischemic attack Vasovagal syncope

    Primary Outcomes

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, and others. Cardiovascular mortality Total mortality

    Measure: Relationship between Blood pressure group and comorbidities

    Time: A 7-year prospective study

    Description: Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, and others. Cardiovascular mortality Total mortality

    Measure: Relationship between adaptability group and comorbidities

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, and others. Cardiovascular mortality Total mortality

    Measure: Relationship between blood pressure group, adaptability group and comorbidities

    Time: A 7-year prospective study

    Secondary Outcomes

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, homoeostasis model assessment (HOMA), total cholesterol, LDL, HDL, triglycerides. Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone Electrocardiogram: HR; PR interval, QRS complex, cQT interval Holter variables: HR, standard deviation of NN intervals (SDNN) and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: Relationship between blood pressure group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides. Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone Electrocardiogram: PR interval, QRS complex, Heart rate, cQT interval Holter variables: HR, SDNN and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: Relationship between blood pressure group, adaptability group, habits anthropometric, metabolic, endocrine, electrocardiographic, Holter, ambulatory arterial blood pressure monitoring.

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: 1) Hyper adaptable, 2) normal adaptability and 3) hypo adaptable. Habits: smoke and drink, exercise Anthropometric variables: Body mass index, waist, hip Metabolic and other variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides; thyrotropine, Holter variables: HR, standard deviation of NN intervals (SDNN) and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: For metabolic disorders what it matters the most: the anthropometric variables vs blood pressure group vs adaptability group

    Time: A 7-year prospective study

    Description: Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides. Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone Electrocardiogram: PR interval, QRS complex, Heart rate, cQT interval Holter variables: HR, SDNN and sympathovagal balance, at day, night and 24 hs. ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge.

    Measure: Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)

    Time: A 7-year prospective study

    Other Outcomes

    Description: Clinical syncope characteristics (age of first syncope, number of syncope episodes, trauma, duration, clinical score, convulse, sphincter relaxation, etc.) Syncope cause Blood pressure group Adaptability group Prognosis

    Measure: Syncope Registry

    Time: Up 100 weeks

    Description: TTT protocol: describe the protocol, the time at positive response, nitroglycerine use, autonomic and hemodynamic variables. TTT outcome for syncope: positive or negative TTT other outcomes: 1) Chronotropic incompetence, 2) arterial orthostatic hypotension, 3) carotid hypersensitivity, 4) POTS, 5) IST The relationship between TTT results and Clinical score for syncope in regard to: syncope behaviour and other orthostatic intolerance entities, symptoms and comorbidities. The relationship between neurally mediated syncope response at the TTT and comorbidities.

    Measure: Tilt table testing (TTT) registry

    Time: Up to 100 weeks

    Description: EPS variables: AH, AV, CL, sino atrial conduction time (SACT), sinus node recovery time (SNRT), corrected sinus node recovery time (CSNRT), response to Isoproterenol, intrinsic heart rate Diagnosis: control, sick sinus syndrome, IST, chronotropic incompetence at the TTT HR at the ECG HR at the Holter monitoring HR at the TTT HRV at the Holter monitoring Syncope, cardiac or neurally mediated HR at the physical treadmill test Relationship with the blood pressure group Relationship with the adaptability group

    Measure: Sinus node function at the electrophysiological study (EPS)

    Time: Up to 100 weeks

    Description: Define how the blood pressure group and/or the adaptability group may add to the already known and include in this registry, in the diagnosis of cardiovascular complications as coronary artery disease, cerebrovascular disease, peripheral artery disease, nephropathy.

    Measure: Score for coronary artery disease

    Time: Up to 200 weeks

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovagal syncope, inappropriate sinus tachycardia, Postural orthostatic syndrome, carotid sinus hypersensitivity; 6) others: chronic fatigue syndrome, fibromyalgia, arthritis, autoimmune diseases, pulmonary thromboembolism, OSA (obstructive sleep apnea), Alzheimer disease, Parkinson disease, others dementias, epilepsia, nephropathies, COPD, and others. Mortality

    Measure: Neurally Mediated Syncope: further of the transient lost of consciousness (TLC)

    Time: A 7-year prospective study

    Description: Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension. Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Psychiatric variables: Big Five Questionary (BFQ) for personality. Modify of the Coping Scale (Scale of modified coping strategies) Zung questionary for depression and anxiety MINI in those patients with moderate or severe depression and/or anxiety at the Zung questionary

    Measure: Psychobiotype: relationship between biological and psychological variables

    Time: Up to 100 weeks

    Description: High sodium intake in the diet is recognized as a risk factor for hypertension development. Essential hypotension population is advised to increase the sodium (at least 10 grams a day) and water intake (at least 2 liters a day), or as much as possible, several have taken Fludrocortisone (is not a exclusion criteria). Normal blood pressure population are advised to have a normal or low sodium intake. Physical exercise is recommended in both groups. This registry is a good opportunity to test how important sodium diet is to induce hypertension, or if by the contrary adaptability could prevail over high sodium intake in this registry. Blood pressure groups: essential hypotension and normotension and those with new essential hypertension. Adaptability groups. The results will be adjusted for age, gender and BMI.

    Measure: The role of high sodium intake in the development of essential hypertension. Comparison between essential hypotension (high sodium intake) vs normotension population (normal or low sodium intake) in the follow-up.

    Time: 4 years

    Description: Consistent bradycardia in the ECG at the office and normal HR in the holter monitoring or the contrary. There are patients with complaints that may be attributed to bradycardia, low blood pressure, hypothyroidism, or other entities. Some patients very often have bradycardia in the ECG taken in the office and normal HR in the 24 Holter monitoring, the opposite is also possible. Patients with bradycardia (without medication or physiological condition as exersice affecting heart rate) in at least 2 ECG (less 60 bpm) and at least 2 Holter monitoring will be analyzed, Other variables to consider are: Age, gender, blood pressure group, adaptability group, maximum HR in the treadmill test, white coat or masked hypertension, Tilt-Table-test result or syncope cause, Electrophysiological study if available. The acknowledge of this phenomenon could have clinical implications in the diagnosis of sick sinus syndrome and physiopathological ones.

    Measure: White coat effect in the heart rate or masked bradycardia.

    Time: 1 year

    Description: Bradycardia is the classical presentation form for sinus node dysfunction, mainly when associated with symptoms. Chronotropic incompetence is also a manifestation. Absence of medications with effects on the heart rate (HR) must be ruled out. Variables HR at the ECG, Holter monitoring, stress text, and at the physical examination previous to pacemaker implantation, Electrophysiological study (EPS): Basic cycle length, Sino-atrial conduction time, Sinus node recovery time, Corrected sinus node recovery time, Intrinsic HR when available 3. Pacemaker variables: HR at day and night or rest time Percentage of stimulation in A and V chambers 4. Syncope: Clinical characteriscs and clinical score Tilt table test results Trans Thoracic Echocardiogram in rest and or stress text Hypothesis: patients with ANSD will start to decrease the percentage atrial stimulation.

    Measure: Reversible Bradycardia Mimicking Sinus Node Dysfunction as a Manifestation of Subacute Autonomic Nervous System Dysfunction (ANSD).

    Time: 2 years

    Description: A non invasive, beat to beat BP monitoring, with the ability to measure BP, HR, Cardiac Output and Systemic Vascular Resistance (SVR) was started to use in the EHAR registry since May 2017. A description of this variables in the three BP groups will be collected in the data base (DB). This will allow to characterize whether SVR and/or CO maintain BP. Until now BP levels are related with prognosis. In the prognosis model SVR and CO will be add them to know what matter the most: BP levels, SVR and/or CO? In the EHAR registry a collection of the variables recognized as a risk factor for several comorbidities are available to adjust in multivariable analysis.

    Measure: Description of the blood pressure hemodynamic profile at a medical office and their prognostic implications.

    Time: Three years
    2 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia

    The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life. Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration. Long-term safety of Ad5FGF-4 will also be assessed.

    NCT02928094
    Conditions
    1. Angina, Stable
    Interventions
    1. Biological: Ad5FGF-4
    2. Biological: Placebo
    MeSH:Angina Pectoris Myocardial Ischemia Coronary Artery Disease Angina, Stable Ischemia
    HPO:Angina pectoris Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: Modified Bruce Protocol with exercise duration limited by angina or angina equivalent

    Measure: Change in Exercise Tolerance Test (ETT) duration

    Time: Baseline and Month 6

    Secondary Outcomes

    Description: Canadian Cardiovascular Society (CCS) angina classification

    Measure: Change in patient functional status (CCS class)

    Time: Baseline and Month 6

    Description: Average weekly angina episodes

    Measure: Change in weekly angina frequency

    Time: Baseline and Month 6

    Description: Average weekly nitroglycerin usage

    Measure: Change in weekly nitroglycerin usage

    Time: Baseline and Month 6

    Description: Seattle Angina Questionnaire

    Measure: Change in quality of life

    Time: Baseline and Month 6

    Description: Adverse events and clinical laboratory testing

    Measure: Safety of Ad5FGF-4

    Time: Through Month 6

    Description: Occurrence of clinically significant events

    Measure: Long-term safety of Ad5FGF-4

    Time: Through Month 60
    3 CSP #599 - Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)

    The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).

    NCT03229941
    Conditions
    1. Myocardial Infarction
    2. Coronary Revascularization
    3. Acute Renal Failure
    Interventions
    1. Procedure: Blood Transfusion
    MeSH:Acute Kidney Injury Myocardial Infarction Infarction
    HPO:Acute kidney injury Myocardial infarction

    Primary Outcomes

    Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.

    Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization.

    Time: 90 days after randomization

    Secondary Outcomes

    Description: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively. Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy. Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.

    Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis.

    Time: 90 days after randomization

    Description: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded. CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment. Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.

    Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no

    Time: 90 days after randomization

    Description: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.

    Measure: All-cause mortality at 1 year after randomization.

    Time: 12 months after randomization

    Description: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.

    Measure: A composite endpoint of all-cause mortality,

    Time: 30 days after randomization

    Description: Length of hospital stay

    Measure: Length of hospital stay.

    Time: At hospital discharge, up to 1 year

    Other Outcomes

    Description: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure

    Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint.

    Time: 90 days after randomization
    4 Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease (The FAVOR III China Study)

    The overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.

    NCT03656848
    Conditions
    1. Coronary Artery Disease
    2. Myocardial Ischaemia
    3. Coronary Circulation
    4. Coronary Stenosis
    5. Percutaneous Coronary Intervention
    Interventions
    1. Diagnostic Test: QFR
    2. Diagnostic Test: Angiography
    MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease Coronary Stenosis Ischemia
    HPO:Coronary artery atherosclerosis Coronary artery stenosis Myocardial infarction

    Primary Outcomes

    Description: A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization

    Measure: MACE

    Time: 1 year

    Secondary Outcomes

    Description: all-cause mortality, any spontaneous myocardial infarction and any ischemia-driven revascularization

    Measure: MACE excluding peri-procedural MI (Major secondary endpoint)

    Time: 1 year

    Description: Cardiovascular, non-cardiovascular and undetermined death

    Measure: Death

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: Target vessel related and non-target vessel related MI

    Measure: MI

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: The ischemia driven and non-ischemia driven TVR

    Measure: Target vessel revascularization (TVR)

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: The The ischemia driven and non-ischemia driven Revascularization

    Measure: Any coronary artery revascularization

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2

    Measure: Definite or probable stent thrombosis

    Time: 1 month, 6 months, 1 year, 2 years and 3 years

    Description: PCI strategy changes following QFR and three-dimension quantitative coronary angiography (3D-QCA)

    Measure: The PCI strategy changes based on the QFR and 3D-QCA

    Time: During the procedure

    Description: Costs include direct clinical costs during the initial hospitalization and other resources used, main cardiovascular medication expenses, and outpatient and/or hospitalization expenses associated with MACE.

    Measure: Cost during 1-year follow-up

    Time: 1 month, 6 months, 1 year

    Description: QALYs determined using EuroQol five dimensions questionnaire (EQ-5D) in official Chinese version, to assess the quality of life.

    Measure: Quality-adjusted-life-years (QALYs) index

    Time: 1 month, 6 months, 1 year
    5 In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer

    To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. The investigators aim to further the mechanistic understanding of atherothrombosis by studying the activation of glycoprotein IIb/IIIa receptors in cardiovascular thrombus using the novel platelet radiotracer (18F-GP1). Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.

    NCT03943966
    Conditions
    1. Thrombosis
    2. Atherothrombosis
    3. Myocardial Infarction
    4. STEMI
    5. NSTEMI - Non-ST Segment Elevation MI
    6. DVT
    7. Pulmonary Embolism
    8. Stroke
    9. Transient Ischemic Attack
    10. Prosthetic Valve Thrombosis
    11. PET
    Interventions
    1. Diagnostic Test: 18F-GP1 PET CT
    MeSH:Pulmonary Embolism Ischemic Attack, Transient Myocardial Infarction Thrombosis Embolism Infarction
    HPO:Myocardial infarction Pulmonary embolism Transient ischemic attack

    Primary Outcomes

    Description: Expression of the glycoprotein IIb/IIIa receptor (assessed by SUV) within thrombus in the arterial and venous circulation.

    Measure: Ratio of 18F-GP1 standardised uptake values (SUV's) in thrombus compared with the SUVs recorded in the blood pool.

    Time: 6 months from end of recruitment

    Secondary Outcomes

    Description: Expression of the glycoprotein IIb/IIIa receptor (assessed by SUV) within thrombus in the arterial and venous circulation in all 5 disease states

    Measure: Ratio of 18F-GP1 standardised uptake values (SUV's) in thrombus formed in each of the 5 disease states.

    Time: 6 months from end of recruitment
    6 A Phase 2 Open Label Study to Assess the PK and PD Properties of a Single Subcutaneous Injection of RUC-4 in Patients With a ST-elevation Myocardial Infarction Presenting to the Cardiac Catheterization Lab With Planned Primary Coronary Angioplasty

    RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. This study is designed to extend the findings in CEL-01 to patients with ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization laboratory with planned coronary angioplasty.

    NCT04284995
    Conditions
    1. Coronary Disease
    2. Myocardial Infarction
    3. Heart Diseases
    4. Vascular Diseases
    5. STEMI - ST Elevation Myocardial Infarction
    Interventions
    1. Drug: RUC-4 Compound
    MeSH:Heart Diseases Myocardial Infarction Vascular Diseases Coronary Disease ST Elevation Myocardial Infarction Infarction
    HPO:Myocardial infarction

    Primary Outcomes

    Description: Inhibition of Platelet Aggregation

    Measure: Platelet Inhibition

    Time: Baseline

    Description: Inhibition of Platelet aggregation

    Measure: Platelet Inhibition

    Time: 15 minutes

    Description: Inhibition of Platelet aggregation

    Measure: Platelet inhibition

    Time: 45 minutes

    Description: Inhibition of Platelet aggregation

    Measure: Platelet inhibition

    Time: 60 minutes

    Description: Inhibition of Platelet aggregation

    Measure: Platelet inhibition

    Time: 90 minutes

    Description: Inhibition of Platelet aggregation

    Measure: Platelet inhibition

    Time: 120 minutes

    Description: Inhibition of Platelet aggregation

    Measure: Platelet inhibition

    Time: 180 minutes

    Description: concentration in blood (ng/mL)

    Measure: RUC-4 Concentration

    Time: Baseline

    Description: concentration in blood (ng/mL)

    Measure: RUC-4 Concentration

    Time: 15 minutes

    Description: concentration in blood (ng/mL)

    Measure: RUC-4 Concentration

    Time: 45 minutes

    Description: concentration in blood (ng/mL)

    Measure: RUC-4 Concentration

    Time: 90 minutes

    Description: concentration in blood (ng/mL)

    Measure: RUC-4 Concentration

    Time: 120 minutes

    Description: concentration in blood (ng/mL)

    Measure: RUC-4 Concentration

    Time: 180 minutes

    Description: Bleeding events, Injection site reactions,vital signs, ECG, laboratory results

    Measure: Safety and Tolerability

    Time: Baseline

    Description: Bleeding events, Injection site reactions,vital signs, ECG, laboratory results

    Measure: Safety and Tolerability

    Time: Hospital discharge
    7 Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic

    Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.

    NCT04325867
    Conditions
    1. Angina Pectoris
    2. Acute Coronary Syndrome
    3. Coronary Syndrome
    4. Coronary Artery Disease
    5. Angioplasty
    6. Stent Restenosis
    7. Hypertension
    8. Heart Failure, Systolic
    9. Depression, Anxiety
    10. Covid-19
    11. Isolation, Social
    Interventions
    1. Other: Tele-medicine platform
    MeSH:Heart Failure Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Angina Pectoris Heart Failure, Systolic Syndrome
    HPO:Abnormality of the cardiovascular system Angina pectoris Congestive heart failure Coronary artery atherosclerosis Left ventricular dysfunction Myocardial infarction Right ventricular failure

    Primary Outcomes

    Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context

    Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients

    Time: 6 months

    Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);

    Measure: Number of patients included in this platform

    Time: 6 months

    Secondary Outcomes

    Description: Will be the number of sessions per patient multiplied with the number of patients included

    Measure: Number of consultations/sessions given

    Time: 6 months
    8 Screening of Cardiovascular Complications in Patients With COVID-19

    Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

    NCT04335162
    Conditions
    1. COVID
    2. Acute Coronary Syndrome
    3. Myocardial Infarction
    4. Myocarditis
    5. Venous Thromboembolism
    6. Deep Vein Thrombosis
    7. Pulmonary Embolism
    MeSH:Pulmonary Embolism Myocardial Infarction Thrombosis Acute Coronary Syndrome Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Myocarditis
    HPO:Deep venous thrombosis Myocardial infarction Myocarditis Pulmonary embolism Thromboembolism Venous thrombosis

    Primary Outcomes

    Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28

    Measure: Determine the incidence of cardiomyopathies and venous thromboembolism

    Time: 28 days

    Secondary Outcomes

    Description: Incidence of mortality at day 28

    Measure: Mortality

    Time: 28 days

    Description: Number of day of using mechanical ventilation for each patients

    Measure: Duration of mechanical ventilation

    Time: 28 days

    Description: Incidence of shock at day 28

    Measure: shock at day 28

    Time: 28 days

    Description: Number of day in intensive care unit

    Measure: length of stay in the intensive care unit

    Time: 28 days
    9 Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study

    In late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.

    NCT04357314
    Conditions
    1. Myocardial Infarction
    MeSH:Myocardial Infarction Infarction
    HPO:Myocardial infarction

    Primary Outcomes

    Description: Free wall rupture, acute ischemic mitral regurgitation, ventricular septal rupture

    Measure: The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI)

    Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )

    Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020

    Measure: Rates of patients presenting with acute myocardial infarction

    Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )

    Secondary Outcomes

    Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19

    Measure: Patient profile during admission for acute myocardial infarction

    Time: 3 months (between March 1 to May 31

    Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19

    Measure: Medical care times analysis

    Time: 3 months (between March 1 to May 31)

    Description: Delay in minutes from symptom onset and STEMI (ST Segment Elevation Myocardial Infarction) diagnosis; and delay in minutes from onset of symptoms and primary PCI (percutaneous coronary intervention)

    Measure: Medical care times analysis

    Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )

    Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at discharge

    Measure: Clinical evolution of patients

    Time: 3 months (between March 1 to May 31)

    Description: Number of in hospital outcomes including orotracheal intubation, cardiogenic shock, arrhythmias (ventricular tachycardia of ventricular fibrillation) and in hospital cardiac arrest

    Measure: Clinical evolution of patients

    Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )

    Description: Number of patient admitted in cardiology department with STEMI (ST Segment Elevation Myocardial Infarction)

    Measure: STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates

    Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )

    Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19

    Measure: Proportion of patients who underwent systemic thrombolysis

    Time: 3 months (between March 1 to May 31)

    Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19

    Measure: Proportion of patients infected with COVID-19

    Time: 3 months (between March 1 to May 31)
    10 Acute Cardiovascular Events Triggered by COVID-19-Related, Non-infectious Stress The Jordan COVID-9 caRdiovascular Events (JoCORE) Study

    The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

    NCT04368637
    Conditions
    1. Acute Myocardial Infarction
    2. Ventricular Tachycardia
    3. Sudden Cardiac Death
    4. Stroke, Acute
    MeSH:Stroke Myocardial Infarction Tachycardia Tachycardia, Ventricular Death, Sudden, Cardiac Infarction Death
    HPO:Myocardial infarction Stroke Sudden cardiac death Tachycardia Ventricular tachycardia

    Primary Outcomes

    Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.

    Measure: Acute cardiovascular event triggered by COVID-19 stress

    Time: 4 months

    Description: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.

    Measure: Ventricular tachycardia

    Time: 4 months

    Description: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance

    Measure: acute stroke

    Time: 4 months

    Description: Finding an episode of ventricular tachycardia on interrogation of ICD tracing

    Measure: Implantable cardioverter defibrillator (ICD) shock

    Time: 4 months
    11 Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses

    Percutaneous cardiovascular intervention procedures (e.g. coronary angioplasty, peripheral artery angioplasty) must be performed in person, requiring the physical presence of one or more medical, nursing and technical professionals. The control of catheters and interventional materials is performed manually, with the operator positioned next to the patient. This context results in potential for reciprocal exposure to exhaled air, both for the professionals involved and for the patient, with an inherent risk of aerial contamination. It is important to note that interventional procedures are often performed on an urgent or emergency basis (e.g. myocardial infarction), without the possibility of postponement or postponement. The recent robot-assisted cardiovascular intervention makes it possible to modify this scenario by allowing the procedure to be performed effectively and safely in a position far from the patient. In an environment with high potential for contamination, mainly related to the current pandemic caused by the COVID-19 virus, may prove to be a tactic to expand hospital security. It is in this sense that the present pilot proposal is inserted, which, ultimately, aims to evaluate the potential of robotic intervention as a strategy to reduce exposure to exhaled air of patients and professionals during the intervention procedure.

    NCT04379453
    Conditions
    1. Coronary Artery Disease
    Interventions
    1. Procedure: Robot Assisted Percutaneous Cardiovascular Intervention
    MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease
    HPO:Coronary artery atherosclerosis Myocardial infarction

    Primary Outcomes

    Description: (arterial dilation with residual lesion <50% at angiography and normal anterograde flow)

    Measure: Successful cardiovascular intervention

    Time: Until the end of the procedure

    Measure: Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention

    Time: Until the end of the procedure

    Measure: absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission

    Time: Until the end of the procedure
    12 International Study on Acute Coronary Syndromes - ST-segment Elevation Myocardial Infarction COVID 19

    The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.

    NCT04412655
    Conditions
    1. ST Elevated Myocardial Infarction Undergoing Mechanical Reperfusion
    Interventions
    1. Device: Percutaneous Coronary Revascularization for STEMI
    MeSH:Myocardial Infarction ST Elevation Myocardial Infarction Infarction
    HPO:Myocardial infarction

    Primary Outcomes

    Description: Number of patients undergoing primary angioplasty

    Measure: Number of patients undergoing primary angioplasty

    Time: March April 2019 and 2020

    Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;

    Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;

    Time: March April 2019 and 2020

    Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission

    Measure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission

    Time: March April 2019 and 2020

    Description: In-Hospital mortality

    Measure: In-hospital mortality

    Time: March April 2019 and 2020
    13 MYocardial DOmmages Related to COVID-19

    Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.

    NCT04498065
    Conditions
    1. Covid19
    2. Non Ischemic Myocardial Injury
    3. Myocardial Infarction
    4. Myocarditis
    5. Troponin Elevation
    Interventions
    1. Biological: Biological data
    2. Other: Clinical data
    MeSH:Myocardial Infarction Myocarditis Infarction
    HPO:Myocardial infarction Myocarditis

    Primary Outcomes

    Description: Myocardtitis diagnosis in patients COVID+ and troponin+

    Measure: characterize the myocardial damage associated with CoV-2 SARS infection

    Time: Through study completion, an average of 1 year
    14 EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

    The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.

    NCT04498091
    Conditions
    1. Acute Myocardial Infarction
    Interventions
    1. Biological: Biological data
    2. Other: Clinical data
    MeSH:Myocardial Infarction Infarction
    HPO:Myocardial infarction

    Primary Outcomes

    Measure: Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection

    Time: Through study completion, an average of 1 year

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook